CompletedPhase 4NCT03344159

Spironolactone Therapy in Chronic Stable Right HF Trial

Studying Dextrocardia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ottawa Heart Institute Research Corporation
Principal Investigator
Lisa Mielniczuk, MD
Ottawa Heart Institute Research Corporation
Intervention
Spironolactone(drug)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
20182024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03344159 on ClinicalTrials.gov
← Back to all trials